Why do we recommend RGCC?

Over the last 12 years, RGCC exams have emerged to be one of the most accurate and complete tests in Liquid Biopsy, which has been seen to date. The test is conducted in Greece by Dr. Ioannis Papasotiriou, MD, PhD, scientific director of RGGC Ltd. and has been perfected over the years. With the use of a simple blood sample, RGCC can work with all types of cancer (solid tumors, blood cancer, sarcomas, etc.) except brain and primary tumors of the nervous system.


The field of oncology has become highly competitive over the past 4-5 years due to an early paradigm shift, based on a huge lack of predictable good results. Large international cancer centers have begun to develop similar tests in the past 4 years, estimating that they could begin to be used in about 5 to 10 years. At this point, none of these centers or any others that have managed to reach the accuracy that the RGCC Lab of Greece make from only 15-20ml of blood.

We know that cancer is metastasizing [spreading] in most cancer patients for many, many years with few perceptual changes. Until recently, no one knew for certain how or why this happened, very often. Now many scientists around the world are finding out that it is due to Tumor Trunk Cells and Circulating Tumor Cells (CSCs / CTCs).


This is fast becoming the focus of many cancer research, in which it aims to stop CSCs and CTCs from causing metastatic tumors that account for at least 90% of all cancer-related deaths. In addition, many scientists suspect that CTCs and CSCs are the cause of almost or all of the metastases that occur. With this new information, circulating CTCs and CSCs are becoming the primary target of oncologists.


The cancer tumor is bad enough, but it's the CSCs and CTCs that are the real problem. These cells are responsible for the metastasis and return of this chronic and systemic disease. Over the past 42 years, trillions of dollars have been spent on cancer research and treatments since the war on cancer was declared in 1971. The overall results of these efforts, time and money, result in only increasing the survival rate of 2 , 1 to 7.5% in 5 years. All this time, money spent, suffering and death of patients, is not something that would be a source of pride and definitely not a good return on the billions or trillions of dollars that were invested.